While COVID vaccine-induced neutralizing antibody responses protect against SARS-CoV-2 infection, control of viral replication is mediated by responses that involve T cells and the antibody-binding Fc receptor.
A single dose of Regeneron Pharma's antibody cocktail casirivimab and imdevimab (trade name Regen-Cov) reduced the risk of COVID-19 by 81.6% for up to eight months, according to a Phase 3 trial.
Differences in lung-specific antibodies and antibody-secreting cells may be one of the important factors determining severe vs mild symptoms from respiratory infections.
The FDA will review an sBLA for Dupixent (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.
Read More
The first Phase 1 clinical trial of two monoclonal antibodies to treat Middle East respiratory syndrome coronavirus (MERS-CoV) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
Read More
People who have had evidence of a prior infection with SARS-CoV-2 appear to be well protected against being reinfected with the virus, at least for a few months.
Read More
The FDA authorized Eli Lilly and Co’s bamlanivimab and etesevimab, monoclonal antibodies for the treatment of mild to moderate COVID-19.
Read More
Pregnant women infected with COVID-19 who were either asymptomatic or symptomatic passed SARS-CoV-2 antibodies to their newborns during pregnancy via the placenta.
Read More
Patients who recover from COVID-19 are protected against the virus for at least six months, and likely much longer, according to a study published in Nature by researchers at Rockefeller University.
Read More
A new COVID-19 antibody assay was able to detect IgG and IgM antibodies to determine viable donor samples for therapeutic use and clinical trials.
Read More
A Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy used for COVID-19.
Read More
The FDA issued an emergency use authorization for Regeneron’s casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in patients 12 and older.
Read More
Scientists have found that some people have antibodies against parts of their own immune system, allowing viruses to multiply rapidly.
Read More
The monoclonal antibody bamlanivimab reduced COVID-19-related hospitalization or ER visits in patients at high risk for disease progression within 28 days after treatment.
Read More
Researchers at the University of Amsterdam conducted a study of human coronaviruses and found that post-infection immunity was not lasting, with reinfections at 12 months and as early as six months later.
Read More